Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.38 |
| ▸ | USP2 | O75604 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.38 |
| ▸ | TP53 | P04637 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | PKM | P14618 | 1/20 | 0.36 |
| ▸ | ABCG2 | Q9UNQ0 | 1/20 | 0.35 |
| ▸ | HPGD | P15428 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5995448 | 0.93 | PKM (0.38) | SMN1; SMN2KMT2APKM | |
| SCHEMBL5995238 | 0.89 | CYP3A4 (0.36) | CYP3A4USP2MAPK1SMN1; SMN2TP53 | |
| SCHEMBL5994238 | 0.89 | ABCG2 (0.40) | CYP3A4USP2MAPK1SMN1; SMN2TP53 | |
| SCHEMBL5995341 | 0.87 | CA12 (0.40) | CYP3A4MAPK1KMT2APKM | |
| SCHEMBL5997395 | 0.87 | TP53 (0.50) | SMN1; SMN2TP53KMT2APKMHPGD | |
| SCHEMBL5994583 | 0.87 | CYP3A4 (0.42) | CYP3A4USP2MAPK1SMN1; SMN2KMT2A | |
| SCHEMBL5993505 | 0.86 | CYP3A4 (0.34) | CYP3A4USP2MAPK1SMN1; SMN2TP53 | |
| SCHEMBL5994847 | 0.85 | TAS1R3 (0.33) | KMT2APKM | |
| SCHEMBL275128 | 0.85 | KMT2A (0.38) | MAPK1SMN1; SMN2KMT2AHPGD | |
| SCHEMBL5994270 | 0.85 | TAS1R3 (0.39) | KMT2APKMHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7026017-B2 | Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2006-04-11 | — | — | US | disclosed |
| US-6969733-B2 | Photoinitiators | CIBA SPECIALTY CHEMICALS CORPORATION (US) | 2005-11-29 | — | — | US | disclosed |
| US-6737549-B2 | PHOTOINITIATORS FOR ACRYLATE COATINGS | CIBA SPECIALTY CHEMICALS CORPORATION | 2004-05-18 | — | — | US | disclosed |
| US-20030139485-A1 | Photoinitiators | WOLF JEAN-PIERRE (CH) | 2003-07-24 | — | — | US | disclosed |
| US-20030130370-A1 | Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation | WOLF JEAN-PIERRE (CH) | 2003-07-10 | — | — | US | disclosed |
| US-20020026049-A1 | Photoinitiators for acrylate coatings | CIBA SPECIALTY CHEMICALS CORP. | 2002-02-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030139485-A1 | Photoinitiators | DHCR24, NR1I3, CBR1 | CYP3A4 432/4885USP2 4345/4885MAPK1 1788/4885 |
| US-20030130370-A1 | Photoinitiators for acrylic esters; reacting an acyl halide with a metal benzoyl phosphine; cable coatings, screen printing stencils, resist materials, colour filters, electrical encapsulation | SMARCC1, ARPC5L, DHCR24 | CYP3A4 2973/4885USP2 4183/4885MAPK1 444/4885 |
| US-20020026049-A1 | Photoinitiators for acrylate coatings | DHCR24, NR5A1, NR2C2 | CYP3A4 946/4885USP2 3795/4885MAPK1 1524/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.